What is CJC-1295?

The short answer

CJC-1295 is a lab-made, longer-lasting copy of part of the body's signal to make growth hormone.

What it is
Long-acting GHRH analog that binds the GHRH receptor.
What people look into
Muscle and exercise, aging, sleep

8 sources
Status as of October 4, 2026
How we source
Ellum doesn't sell peptides.

By Ellum EditorialPublished October 6, 2026Updated October 11, 2026AI use

Get updates on CJC-1295

State

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: CJC-1295 (1 selected) · edit

Peptides you're interested inCJC-1295

Add another molecule

What we may email you about

Notify me when an Ellum Clinic doctor can see me in my state

Send me updates on CJC-1295

More options (optional): research, doctor contact, paid offers

Contact me about taking part in research (optional)

Send my email, state and peptides to Ellum Clinic or a doctor licensed in my state, so they can contact me about care (optional)

Email me paid offers from clinics and health companies, picked for my peptides and state. Ellum sends them; the companies don't get my details (optional)

What it is

Type: GHRH analog (peptide; with or without DAC)
Also known as: cjc-1295 dac, cjc 1295 no dac, mod grf 1-29
How it works: Long-acting GHRH analog that binds the GHRH receptor.

Regulatory status

Not FDA-approved How we label status

As of October 4, 2026, CJC-1295 is not FDA-approved for any use and is not on FDA's 503A bulks list.

See CJC-1295 in the Index →

Federal (FDA): Not FDA-approved
503A compounding: No category (nomination withdrawn; removed from Cat 2 2024-09-27); not on 216.23 as of 2026-10-07; not an approved-drug component (as of October 7, 2026)
PCAC history: 2024-12-04: against (free base 0-13; acetate 1-12; DAC forms 0-13 each; use reviewed: GHD); FDA staff: against
WADA 2026: S2.2.4

Timeline

Scroll sideways to see all columns.

Date	What happened	Source
October 25, 2024	Federal Register notice of an FDA Pharmacy Compounding Advisory Committee meeting lists CJC-1295 (with and without DAC) among bulk drug substances under consideration for the 503A bulks list.	Federal Register, event of October 25, 2024, on federalregister.gov

US enforcement actions

1 US enforcement action, in 2026.

Actions by US federal and state agencies whose documents name CJC-1295. Each row links to the government's own document.

Scroll sideways to see all columns.

Date	Agency	Action	Document
April 1, 2026	US Justice Department	Indictment	Justice Department document, indictment, April 1, 2026, on justice.gov

References

Sources as of October 4, 2026